Neurocrine Biosciences Inc
NBIX128.020USD
-0.890-0.69%
交易中 （美东）报价延迟15分钟
12.67B总市值
41.45市盈率 TTM
关于 Neurocrine Biosciences Inc 公司
Neurocrine Biosciences, Inc. 是一家专注于神经科学的生物制药公司。该公司致力于发现和开发治疗神经、神经内分泌和神经精神疾病的药物，这些疾病尚未得到充分治疗。其多元化的产品组合包括美国食品药品管理局批准的治疗迟发性运动障碍、与亨廷顿氏病相关的舞蹈症、子宫内膜异位症和子宫肌瘤的药物，以及强大的产品线，包括多个处于中后期临床开发阶段的化合物，涉及其核心治疗领域。其商业产品包括 INGREZZA、ALKINDI、EFMODY、Orilissa 和 Oriahnn。INGREZZA 在日本以 DYSVAL（伐贝那嗪）的名称销售，在其他特定亚洲市场以 REMLEAS（伐贝那嗪）的名称销售，三菱田边制药株式会社保留这些市场的商业化权利。 ALKINDI 在美国以 ALKINDI SPRINKLE（氢化可的松）的名称销售，Eton Pharmaceuticals, Inc. 保留其商业化权利。
公司简介
公司代码NBIX
公司名称Neurocrine Biosciences Inc
上市日期May 23, 1996
CEODr. Kyle W. Gano, Ph.D.
员工数量1800
证券类型Ordinary Share
年结日May 23
公司地址6027 Edgewood Bend Court
城市SAN DIEGO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编92130
电话18586177600
网址https://www.neurocrine.com/
公司代码NBIX
上市日期May 23, 1996
CEODr. Kyle W. Gano, Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Kyle W. Gano, Ph.D.
Dr. Kyle W. Gano, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
140.11K
+0.14%
Mr. Gary A. Lyons
Mr. Gary A. Lyons
Independent Director
Independent Director
120.48K
+1.21%
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
40.36K
+7.65%
Mr. Matthew C. Abernethy, CPA
Mr. Matthew C. Abernethy, CPA
Chief Financial Officer
Chief Financial Officer
35.81K
--
Mr. Richard F. Pops
Mr. Richard F. Pops
Independent Director
Independent Director
34.48K
+9.08%
Mr. Darin M. Lippoldt, J.D.
Mr. Darin M. Lippoldt, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.10K
+8.90%
Dr. Jude Onyia, Ph.D.
Dr. Jude Onyia, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
18.29K
--
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
13.54K
+26.88%
Mr. George J. Morrow
Mr. George J. Morrow
Independent Director
Independent Director
7.07K
+68.33%
Ms. Johanna Mercier
Ms. Johanna Mercier
Independent Director
Independent Director
3.54K
+68.33%
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Kyle W. Gano, Ph.D.
Dr. Kyle W. Gano, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
140.11K
+0.14%
Mr. Gary A. Lyons
Mr. Gary A. Lyons
Independent Director
Independent Director
120.48K
+1.21%
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
40.36K
+7.65%
Mr. Matthew C. Abernethy, CPA
Mr. Matthew C. Abernethy, CPA
Chief Financial Officer
Chief Financial Officer
35.81K
--
Mr. Richard F. Pops
Mr. Richard F. Pops
Independent Director
Independent Director
34.48K
+9.08%
Mr. Darin M. Lippoldt, J.D.
Mr. Darin M. Lippoldt, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
31.10K
+8.90%
收入明细
FY2024
FY2023
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
INGREZZA
2.31B
0.00%
Other
17.10M
0.00%
暂无数据
业务
地区
业务USD
名称
营收
占比
INGREZZA
2.31B
0.00%
Other
17.10M
0.00%
股东统计
更新时间: 5月15日 周四
更新时间: 5月15日 周四
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
10.87%
The Vanguard Group, Inc.
9.98%
Dodge & Cox
5.58%
State Street Global Advisors (US)
4.90%
Renaissance Technologies LLC
2.52%
Other
66.15%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
10.87%
The Vanguard Group, Inc.
9.98%
Dodge & Cox
5.58%
State Street Global Advisors (US)
4.90%
Renaissance Technologies LLC
2.52%
Other
66.15%
股东类型
持股股东
占比
Investment Advisor
44.97%
Investment Advisor/Hedge Fund
33.61%
Hedge Fund
11.66%
Pension Fund
2.53%
Research Firm
2.09%
Bank and Trust
1.46%
Individual Investor
1.06%
Private Equity
1.05%
Family Office
0.56%
Other
1.01%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
1305
98.03M
98.85%
-6.73M
2025Q1
1337
99.69M
100.72%
-4.46M
2024Q4
1312
98.79M
98.90%
-3.53M
2024Q3
1263
97.40M
96.49%
-4.44M
2024Q2
1241
97.92M
97.33%
-1.65M
2024Q1
1200
97.20M
96.69%
-3.28M
2023Q4
1158
96.37M
98.09%
-3.68M
2023Q3
1123
95.61M
97.90%
-5.53M
2023Q2
1101
95.03M
97.40%
-6.72M
2023Q1
1121
95.04M
97.47%
-5.05M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
10.78M
10.89%
-179.10K
-1.63%
Mar 31, 2025
The Vanguard Group, Inc.
9.90M
10%
-228.88K
-2.26%
Mar 31, 2025
Dodge & Cox
5.53M
5.59%
+2.52M
+83.48%
Mar 31, 2025
State Street Global Advisors (US)
4.86M
4.91%
-29.02K
-0.59%
Mar 31, 2025
Renaissance Technologies LLC
2.50M
2.53%
+13.30K
+0.53%
Mar 31, 2025
Wellington Management Company, LLP
2.10M
2.12%
+640.56K
+43.95%
Mar 31, 2025
JP Morgan Asset Management
2.03M
2.05%
+985.43K
+94.16%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.97M
1.99%
+94.69K
+5.05%
Mar 31, 2025
Bellevue Asset Management AG
1.82M
1.84%
--
--
Mar 31, 2025
Deerfield Management Company, L.P.
1.49M
1.5%
+627.00K
+72.74%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Tema Neuroscience and Mental Health ETF
4.95%
Simplify Health Care ETF
4.48%
AdvisorShares Psychedelics ETF
4.41%
iShares Neuroscience and Healthcare ETF
4.39%
First Trust NYSE Arca Biotechnology Index Fund
4.35%
VanEck Biotech ETF
2.85%
Invesco Biotechnology & Genome ETF
2.72%
Goldman Sachs Future Health Care Equity ETF
2.52%
SPDR S&P Biotech ETF
2.46%
Alger Russell Innovation ETF
2.21%
查看更多
Tema Neuroscience and Mental Health ETF
占比4.95%
Simplify Health Care ETF
占比4.48%
AdvisorShares Psychedelics ETF
占比4.41%
iShares Neuroscience and Healthcare ETF
占比4.39%
First Trust NYSE Arca Biotechnology Index Fund
占比4.35%
VanEck Biotech ETF
占比2.85%
Invesco Biotechnology & Genome ETF
占比2.72%
Goldman Sachs Future Health Care Equity ETF
占比2.52%
SPDR S&P Biotech ETF
占比2.46%
Alger Russell Innovation ETF
占比2.21%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
